AMRI Stock Tumbles After Announcing B-MS Trial Ends

By Zachary Brennan

- Last updated on GMT

AMRI Stock Tumbles After Announcing B-MS Trial Ends
Albany Molecular Research's (AMRI) stock fell more than 10% on Monday after announcing in an SEC filing that it was informed by its partner Bristol-Myers Squibb that it would terminate the development of an investigational depression drug.

But the decision to cease the drug’s development, which was in Phase II of clinical development, is expected to “have no impact on AMRI’s financial guidance or forecasts, including, the company’s financial guidance for the third quarter and full year 2013​,” AMRI said.

The partnership between AMRI and BMS began in 2005 and has been a source of revenue for AMRI in the past due to payments for research and milestones reached on some compounds.

The drug in question was a triple reuptake inhibitor in development for treatment-resistant depression.

The announcement of the trial’s end comes as the company recently received a Form 483 at its Burlington, Massachusetts, plant​ after the US FDA re-inspected it.  

Despite these setbacks, AMRI CEO Thomas D’Ambra said last week in an earnings call​ that the company still expects to be profitable by the end of the year.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars